Zimmer Biomet Holdings announced that the FDA has approved Persona IQ, which will enable ZBH to launch the world’s first intelligent implant that can completely replace the knee joint. Persona IQ will be a significant addition to ZBEdge ZBH’s growing portfolio, contributing to the expected acceleration in Kneefranchise’s revenue growth
TIKR
ZBH
PRICE
$150
TARGET PRICE
$175
UPSIDE
17%
For years, the lack of new developments has limited ZBH’s sales growth. Through the merger with Biomet and the ongoing refinement of the Persona knee system, ZBH has more opportunities to capture market share and strengthen its research business. In our opinion, ZBH’s decision to spin off Spine and Dental in 2021 will improve the company’s financial profile and open up opportunities for ZBH to sustainably grow profitably in the future, which will support market capitalization.
ZBH designs and sells reconstructive and trauma devices. The company also has biologic, sports medicine, dental, bone healing and micro fixation, and related surgical devices in its product portfolio. ZBH manages its operations through three geographic segments: the Americas, which consists of the United States and includes other North, Central and South American markets; Europe, which consists of Europe and includes the Middle East and Africa markets, and Asia Pacific, which comprises Japan, Australia and select other markets. Zimmer merged with Biomet in June 2015, greatly expanding its orthopedic scale.